- Investing Ideas
- Swedish Pharmaceuticals & Biotech Undervalued over 20% based on DCF
Swedish Pharmaceuticals & Biotech Undervalued over 20% based on DCF
Results
6
Companies which are undervalued more than 20% based on the Discounted Cash Flow valuation.
6 companies
AddLife
Market Cap: SEK 17.9b
Provides equipment, consumables, and reagents primarily to medical care, research, colleges and universities, as well as the food and pharmaceutical industries.
ALIF B
SEK 146.80
7D
3.4%
1Y
2.1%
Bonesupport Holding
Market Cap: SEK 15.3b
An orthobiologics company, develops and sells injectable bio-ceramic bone graft substitutes in Europe, North America, and internationally.
BONEX
SEK 229.20
7D
7.0%
1Y
-23.2%
Vitrolife
Market Cap: SEK 12.9b
Provides assisted reproduction products in Europe, the Middle East, Africa, Asia-Pacific, and the Americas.
VITR
SEK 95.30
7D
2.7%
1Y
-37.1%
BioGaia
Market Cap: SEK 12.1b
A healthcare company, develops, manufactures, markets and sells probiotic products for gut, oral, and immune health in Europe, the Middle East, Africa, the United States, the Asia-Pacific, Australia, and New Zealand.
BIOG B
SEK 119.40
7D
2.1%
1Y
21.2%
Genovis AB (publ.)
Market Cap: SEK 1.3b
Develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia.
GENO
SEK 18.94
7D
-2.6%
1Y
3.4%
Double Bond Pharmaceutical International
Market Cap: SEK 12.9m
A pharmaceutical company, engages in the development and commercialization of approaches for the treatment of oncological and infectious diseases.
DBP B
SEK 0.12
7D
9.1%
1Y
-72.7%